These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 23349911)

  • 1. MicroRNA-mediated suppression of oncolytic adenovirus replication in human liver.
    Ylösmäki E; Lavilla-Alonso S; Jäämaa S; Vähä-Koskela M; af Hällström T; Hemminki A; Arola J; Mäkisalo H; Saksela K
    PLoS One; 2013; 8(1):e54506. PubMed ID: 23349911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumor activity of a miR-199-dependent oncolytic adenovirus.
    Callegari E; Elamin BK; D'Abundo L; Falzoni S; Donvito G; Moshiri F; Milazzo M; Altavilla G; Giacomelli L; Fornari F; Hemminki A; Di Virgilio F; Gramantieri L; Negrini M; Sabbioni S
    PLoS One; 2013; 8(9):e73964. PubMed ID: 24069256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA regulation of oncolytic adenovirus 6 for selective treatment of castration-resistant prostate cancer.
    Zhang Z; Zhang X; Newman K; Liu X; Seth P
    Mol Cancer Ther; 2012 Nov; 11(11):2410-8. PubMed ID: 22914437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells.
    Cawood R; Chen HH; Carroll F; Bazan-Peregrino M; van Rooijen N; Seymour LW
    PLoS Pathog; 2009 May; 5(5):e1000440. PubMed ID: 19461878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
    Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
    Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11.
    Wong HH; Jiang G; Gangeswaran R; Wang P; Wang J; Yuan M; Wang H; Bhakta V; Müller H; Lemoine NR; Wang Y
    Mol Ther; 2012 Feb; 20(2):306-16. PubMed ID: 22086234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting human breast cancer cells by an oncolytic adenovirus using microRNA-targeting strategy.
    Shayestehpour M; Moghim S; Salimi V; Jalilvand S; Yavarian J; Romani B; Mokhtari-Azad T
    Virus Res; 2017 Aug; 240():207-214. PubMed ID: 28867494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus.
    Shashkova EV; Spencer JF; Wold WS; Doronin K
    Mol Ther; 2007 Mar; 15(3):598-607. PubMed ID: 17191072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of microRNA Let-7 to control the replication specificity of oncolytic adenovirus in hepatocellular carcinoma cells.
    Jin H; Lv S; Yang J; Wang X; Hu H; Su C; Zhou C; Li J; Huang Y; Li L; Liu X; Wu M; Qian Q
    PLoS One; 2011; 6(7):e21307. PubMed ID: 21814544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA.
    Ylösmäki E; Hakkarainen T; Hemminki A; Visakorpi T; Andino R; Saksela K
    J Virol; 2008 Nov; 82(22):11009-15. PubMed ID: 18799589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT.
    Doloff JC; Jounaidi Y; Waxman DJ
    Cancer Gene Ther; 2011 Mar; 18(3):153-66. PubMed ID: 20865021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
    Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
    Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.
    Zhang J; Lai W; Li Q; Yu Y; Jin J; Guo W; Zhou X; Liu X; Wang Y
    Biochem Biophys Res Commun; 2017 Sep; 491(2):469-477. PubMed ID: 28698142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.
    Xu HN; Huang WD; Cai Y; Ding M; Gu JF; Wei N; Sun LY; Cao X; Li HG; Zhang KJ; Liu XR; Liu XY
    Mol Cancer; 2011 Nov; 10():133. PubMed ID: 22040050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel oncolytic adenovirus based on simian adenovirus serotype 24.
    Cheng T; Song Y; Zhang Y; Zhang C; Yin J; Chi Y; Zhou D
    Oncotarget; 2017 Apr; 8(16):26871-26885. PubMed ID: 28460470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-148a- and miR-216a-regulated oncolytic adenoviruses targeting pancreatic tumors attenuate tissue damage without perturbation of miRNA activity.
    Bofill-De Ros X; Gironella M; Fillat C
    Mol Ther; 2014 Sep; 22(9):1665-77. PubMed ID: 24895996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic delivery of a novel liver-detargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model.
    Zhang Z; Krimmel J; Zhang Z; Hu Z; Seth P
    Hum Gene Ther; 2011 Sep; 22(9):1137-42. PubMed ID: 21480822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic adenovirus based on serotype 3.
    Hemminki O; Bauerschmitz G; Hemmi S; Lavilla-Alonso S; Diaconu I; Guse K; Koski A; Desmond RA; Lappalainen M; Kanerva A; Cerullo V; Pesonen S; Hemminki A
    Cancer Gene Ther; 2011 Apr; 18(4):288-96. PubMed ID: 21183947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer.
    Nettelbeck DM
    J Mol Med (Berl); 2008 Apr; 86(4):363-77. PubMed ID: 18214411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral genome DNA/lipoplexes elicit in situ oncolytic viral replication and potent antitumor efficacy via systemic delivery.
    Kwon OJ; Kang E; Kim S; Yun CO
    J Control Release; 2011 Oct; 155(2):317-25. PubMed ID: 21699929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.